PDE5A and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: The aggregate results from our study imply that treatment of neurobehavioral symptoms associated with developmental disturbances stemming from dystrophin deficiency and impaired cGMP signaling in the cerebellum may be improved by using either a PDE9A specific inhibitor or a PDE5A inhibitor.